Cristin-resultat-ID: 1931606
Sist endret: 17. februar 2022, 13:58
NVI-rapporteringsår: 2021
Vitenskapelig artikkel

Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study

  • Xiuxia Yuan
  • Yunpeng Wang
  • Xue Li
  • Jiajun Jiang
  • Yulin Kang
  • Lijuan Pang
  • mfl.


Translational Psychiatry
ISSN 2158-3188
e-ISSN 2158-3188
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2021
Publisert online: 2021
Volum: 11
Sider: 1 - 9
Artikkelnummer: 422
Open Access


Scopus-ID: 2-s2.0-85112054600

Beskrivelse Beskrivelse


Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study


Preclinical studies have shown that the gut microbiota can play a role in schizophrenia (SCH) pathogenesis via the gut-brain axis. However, its role in the antipsychotic treatment response is unclear. Here, we present a 24-week follow-up study to identify gut microbial biomarkers for SCH diagnosis and treatment response, using a sample of 107 first-episode, drug-naïve SCH patients, and 107 healthy controls (HCs). We collected biological samples at baseline (all participants) and follow-up time points after risperidone treatment (SCH patients). Treatment response was assessed using the Positive and Negative Symptoms Scale total (PANSS-T) score. False discovery rate was used to correct for multiple testing. We found that SCH patients showed lower α-diversity (the Shannon and Simpson’s indices) compared to HCs at baseline (p = 1.21 × 10−9, 1.23 × 10−8, respectively). We also found a significant difference in β-diversity between SCH patients and HCs (p = 0.001). At baseline, using microbes that showed different abundance between patients and controls as predictors, a prediction model can distinguish patients from HCs with an area under the curve (AUC) of 0.867. In SCH patients, after 24 weeks of risperidone treatment, we observed an increase of α-diversity toward the basal level of HCs. At the genus level, we observed decreased abundance of Lachnoclostridium (p = 0.019) and increased abundance Romboutsia (p = 0.067). Moreover, the treatment response in SCH patients was significantly associated with the basal levels of Lachnoclostridium and Romboutsia (p = 0.005 and 0.006, respectively). Our results suggest that SCH patients may present characteristic microbiota, and certain microbiota biomarkers may predict treatment response in this patient population.


Xiuxia Yuan

  • Tilknyttet:
    ved Zhengzhou University

Yunpeng Wang

  • Tilknyttet:
    ved Psykologisk institutt ved Universitetet i Oslo

Xue Li

  • Tilknyttet:
    ved Zhengzhou University

Jiajun Jiang

  • Tilknyttet:
    ved Kina

Yulin Kang

  • Tilknyttet:
    ved Chinese Research Academy of Environmental Sciences
1 - 5 av 13 | Neste | Siste »